Takeda Pharmaceutical Company Limited - Asset Resilience Ratio

Latest as of September 2025: 0.40%

Takeda Pharmaceutical Company Limited (TKDA) has an Asset Resilience Ratio of 0.40% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€58.19 Billion
Cash + Short-term Investments

Total Assets

€14.47 Trillion
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Takeda Pharmaceutical Company Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Takeda Pharmaceutical Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €58.19 Billion 0.4%
Total Liquid Assets €58.19 Billion 0.40%

Asset Resilience Insights

  • Limited Liquidity: Takeda Pharmaceutical Company Limited maintains only 0.40% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Takeda Pharmaceutical Company Limited Industry Peers by Asset Resilience Ratio

Compare Takeda Pharmaceutical Company Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Dongwha Pharm.Co.Ltd
KO:000020
Drug Manufacturers - Specialty & Generic 1.72%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.46%
Yuhan Corp Preferred
KO:000105
Drug Manufacturers - Specialty & Generic 0.99%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%
Kotra Industries Bhd
KLSE:0002
Drug Manufacturers - Specialty & Generic 9.82%
Yuyu Pharma
KO:000220
Drug Manufacturers - Specialty & Generic 1.74%
Ildong Holdings Co Ltd
KO:000230
Drug Manufacturers - Specialty & Generic 1.57%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%

Annual Asset Resilience Ratio for Takeda Pharmaceutical Company Limited (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Takeda Pharmaceutical Company Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.14% €20.48 Billion €14.25 Trillion +0.04pp
2024-03-31 0.10% €15.09 Billion €15.11 Trillion -0.04pp
2023-03-31 0.14% €20.17 Billion €13.96 Trillion -0.05pp
2022-03-31 0.19% €25.30 Billion €13.18 Trillion -0.09pp
2021-03-31 0.28% €36.60 Billion €12.91 Trillion +0.16pp
2020-03-31 0.12% €15.82 Billion €12.82 Trillion -0.04pp
2019-03-31 0.17% €23.28 Billion €13.87 Trillion -1.80pp
2018-03-31 1.96% €80.65 Billion €4.11 Trillion +0.66pp
2017-03-31 1.30% €56.68 Billion €4.36 Trillion --
pp = percentage points

About Takeda Pharmaceutical Company Limited

F:TKDA Germany Drug Manufacturers - Specialty & Generic
Market Cap
$55.03 Billion
€47.07 Billion EUR
Market Cap Rank
#626 Global
#86 in Germany
Share Price
€14.90
Change (1 day)
-0.67%
52-Week Range
€11.30 - €16.10
All Time High
€16.10
About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more